<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>a2040697zex-2_1.htm
<DESCRIPTION>AMENDMENT TO PURCHASE AGREEMENT
<TEXT>

<HTML>
<HEAD>
<TITLE> Prepared by MERRILL CORPORATION www.edgaradvantage.com
</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#01CHI1831_2">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="page_kc1831_1_1"> </A> </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kc1831_amendment_to_purchase_agreement"> </A>
<A NAME="toc_kc1831_1"> </A>
<BR></FONT><FONT SIZE=2><B>Amendment to Purchase Agreement    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;This AMENDMENT TO PURCHASE AGREEMENT dated as of March&nbsp;2, 2001 (this "Amendment") is between BASF Aktiengesellschaft ("Seller") and Abbott Laboratories
("Purchaser"). </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>W&nbsp;I&nbsp;T&nbsp;N&nbsp;E&nbsp;S&nbsp;S&nbsp;E&nbsp;T&nbsp;H:  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Seller and Purchaser are parties to the Purchase Agreement dated as of December&nbsp;14, 2000 (Number 194 of the Roll of Deeds for 2000 of
Dr.&nbsp;Norbert Meister, notar at Frankfurt a.M.) (the "Purchase Agreement") pursuant to which Purchaser has agreed to acquire the Shares and Transferred Patents (as such terms are defined in the
Purchase Agreement); and </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS,
Seller and Purchaser have agreed to certain matters incidental to the consummation of the transactions contemplated by the Purchase Agreement. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;NOW,
THEREFORE, in consideration of the premises and the mutual covenants hereinafter contained, the parties to the Purchase Agreement hereby agree as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kc1831_section_1_definitions"> </A>
<A NAME="toc_kc1831_2"> </A>
<BR></FONT><FONT SIZE=2><B>Section&nbsp;1<BR>  Definitions    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All initial capitalized terms used and not otherwise defined herein have the meanings assigned to such terms in the Purchase Agreement. </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kc1831_section_2_amendments_to_purchase_agreement"> </A>
<A NAME="toc_kc1831_3"> </A>
<BR></FONT><FONT SIZE=2><B>Section&nbsp;2<BR>  Amendments to Purchase Agreement    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Purchase Agreement is hereby amended as follows: </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.1.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Definitions" is hereby amended by adding the following defined terms: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>"BASF
Knoll India Shares" means the Knoll India Shares owned by Lupharma and representing 51% of the total issued and outstanding equity shares of Knoll India. </FONT></P>

<P><FONT SIZE=2>"Hokuriku"
means Hokuriku Seiyaku and Co.&nbsp;Ltd., a Japanese stock corporation. </FONT></P>

<P><FONT SIZE=2>"Knoll
India Base Amount" means the aggregate value derived by multiplying the Knoll India Per Share Base Amount with the number of BASF Knoll India Shares. </FONT></P>


<P><FONT SIZE=2>"Knoll
India Net Assets Amount" has the meaning set forth in Exhibit&nbsp;7.4. </FONT></P>

</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=1,SEQ=1,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=781035,FOLIO='1',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_2"> </A>
<UL>
<UL>

<P><FONT SIZE=2>
"Knoll India Per Share Base Amount" means (i)&nbsp;the Knoll India Per Share Tender Price, less (ii)&nbsp;the Knoll India Per Share Net Assets Amount. </FONT></P>

<P><FONT SIZE=2>"Knoll
India Per Share Net Assets Amount" means (i)&nbsp;the Knoll India Net Assets Amount, divided by (ii)&nbsp;the number of outstanding Knoll India Shares as of the Closing. </FONT></P>

<P><FONT SIZE=2>"Knoll
India Per Share Tender Price" means the price per share offered by Purchaser in the Knoll India Tender Offer. </FONT></P>

<P><FONT SIZE=2>"Knoll
India Shares" means the fully paid, issued and outstanding voting equity shares in the capital of Knoll India, each such share having a par value of Rs. 10. </FONT></P>

<P><FONT SIZE=2>"Knoll
India Tender Offer" means the public offer that Purchaser is required to make to the public shareholders of Knoll India pursuant to the laws of India as a result of Purchaser deciding to
acquire, or acquiring, the BASF Knoll India Shares in accordance with the provisions of this Agreement, as amended. </FONT></P>

<P><FONT SIZE=2>"Knoll
India" means Knoll Pharmaceuticals Limited, a listed public company formed under the laws of India. </FONT></P>

<P><FONT SIZE=2>"Lupharma"
means Lupharma GmbH, a limited liability company under the laws of the Federal Republic of Germany registered in the Commercial Register of the local court Ludwigshafen under docket number
HRB 3617. </FONT></P>

<P><FONT SIZE=2>"Provisional
Knoll India Base Amount" means the amount set forth on Exhibit&nbsp;8.1 for Knoll India. </FONT></P>

<P><FONT SIZE=2>"Transpharm"
means Transpharm GmbH, a limited liability company under the laws of the Federal Republic of Germany registered in the Commercial Register of the local court Ludwigshafen under docket
number HRB 1135. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.2&nbsp;&nbsp;Section&nbsp;5.3
of the Purchase Agreement is hereby amended and restated in its entirety as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>5.3</FONT></DT><DD><FONT SIZE=2>"Shared
Substances" shall mean the substances (Substanzen) contained in the physical compound library of the Seller or its Affiliates (other than
the Companies), on the one hand, and/or Knoll AG, on the other hand, in each case at facilities located in Ludwigshafen, Germany, including, without limitation, any such substances obtained from third
parties. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.3.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;7, Sale" is hereby amended by amending and restating such section in its entirety as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>7.1</FONT></DT><DD><FONT SIZE=2>Seller
hereby sells the Shares and the Transferred Patents to Purchaser or to entities designated by Purchaser, subject to the occurrence and
fulfillment or waiver of all of the Closing Conditions and with commercial </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=2,SEQ=2,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=918978,FOLIO='2',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_3"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>effect
as amongst the parties as of the Closing, and Seller hereby agrees to transfer, or to cause its Affiliates to transfer, the Shares and the Transferred Patents by separate transfer contracts
(hereinafter referred to as "Separate Transfer Contracts") to Purchaser or to entities designated by Purchaser at and effective as of the Closing. Notwithstanding anything to the contrary set forth in
this Agreement, "Shares" shall not include shares or other interests in any of the companies or entities set forth on Exhibit&nbsp;12.2(d). </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>7.2</FONT></DT><DD><FONT SIZE=2>The
Separate Transfer Contracts shall be entered into and completed at the Closing in accordance with Section&nbsp;12.1.
<BR><BR></FONT></DD><DT><FONT SIZE=2>7.3</FONT></DT><DD><FONT SIZE=2>Seller
shall cause the businesses described in clauses (a)&nbsp;through (d)&nbsp;in the definition of "Discontinued/Excluded Businesses" to be
transferred to Seller or any of its Affiliates (other than the Companies) prior to the Closing. To the extent not so transferred, Purchaser shall (a)&nbsp;upon Seller's request and at Seller's
expense cause each such transfer to be made or completed after the Closing as far as not made or completed prior thereto, (b)&nbsp;hold (without any obligation to manage or operate) such
Discontinued/Excluded Businesses until completion of their transfer for the account of Seller and (c)&nbsp;pay any consideration in respect of such transfer to Seller.
<BR><BR></FONT></DD><DT><FONT SIZE=2>7.4</FONT></DT><DD><FONT SIZE=2>Subject
to the second sentence of Section&nbsp;8.3(b), as far as the Knoll India Shares are concerned, the Knoll India Per Share Tender Price
multiplied by the number of BASF Knoll India Shares acquired by Purchaser pursuant hereto (such amount, converted from RS to USD using the Conversion Exchange Rates, being the "Knoll India Purchase
Price") shall determine the total purchase price paid by Purchaser to Seller in respect of, and allocated to, the BASF Knoll India Shares; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT
SIZE=2>, that if such amount as so determined is (a)&nbsp;greater than the amount set forth for Knoll India on Exhibit&nbsp;8.1, then the Knoll
India Purchase Price shall be the amount set forth on such Exhibit, or (b)&nbsp;less than the amount set forth for Knoll India on Exhibit&nbsp;8.1 (the "Knoll India Excess"), such Knoll India
Excess shall be allocated to such Companies (other than Knoll India) as Seller and Purchaser may mutually agree. Exhibit&nbsp;7.4 shall govern the calculation of the Knoll India Net Asset Value
described therein.
<BR><BR></FONT></DD><DT><FONT SIZE=2>7.5</FONT></DT><DD><FONT SIZE=2>The
parties acknowledge that at the Closing, Purchaser shall not acquire the shares of Lupharma UK Holding II,&nbsp;Ltd. (or indirectly shares of
Knoll International Private&nbsp;Ltd. ("Knoll India Private")). Seller hereby grants to Purchaser an option to acquire either the shares of Lupharma UK Holding II,&nbsp;Ltd. (the "Share Option")
or all or substantially all of the assets of Knoll India Private (the "Assets Option") through such entities as Purchaser may elect, including through a less than wholly owned affiliate of Purchaser.
Purchaser shall exercise either the Share Option or the Assets Option no later than December&nbsp;31, 2001. Upon the exercise of </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=3,SEQ=3,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=37506,FOLIO='3',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_4"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>such
Option by Purchaser, each of Purchaser and Seller shall take, or cause to be taken, all actions (including the execution and delivery of documents, instruments and agreements), and to do, or
cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable,
the transactions contemplated by the sale of such assets, including (i)&nbsp;obtaining all necessary actions or non-actions, waivers, consents and approvals from third parties and governmental
entities and making all necessary registrations and filings (including filings with governmental entities) and taking all reasonable steps as may be necessary to obtain any approvals or waivers from,
or avoiding any action or proceeding by, any such third parties or governmental entities, (ii)&nbsp;executing and delivering any additional instruments necessary to consummate the transactions
contemplated by this Section&nbsp;7.5, and to fully carry out the purposes of this Section, and (iii)&nbsp;the engagement of such Indian advisors (including Counsel and accountants) as may be
necessary to fully carry out the purposes of this Section. From and after the Closing through the date of the acquisition contemplated by this Section&nbsp;7.5, Seller
shall operate Knoll India Private in accordance with the terms of this Agreement as if Knoll India Private were a Company referred to in Section&nbsp;12.5. Upon the closing of the transactions
contemplated by the Share Option or the Assets Option, as the case may be, Purchaser shall pay Seller or Seller's Affiliate (including Knoll India Private in the case of the exercise of the Assets
Option) the purchase price for Knoll India Private in the amount set forth on Exhibit&nbsp;8.1 for such entity. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.4.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;8, Purchase Price" is hereby amended by amending and restating such section in its entirety as
follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>8.1</FONT></DT><DD><FONT SIZE=2>Subject
to Section&nbsp;8.2(b) below, the aggregate purchase price for the Shares and Transferred Patents and the license granted in
Section&nbsp;25.1 below shall be USD 6,930,000,000.00 (six billion nine hundred thirty million United States Dollars) (hereinafter referred to as the "Aggregate Purchase Price"), and shall be
allocated, except as otherwise provided in Section&nbsp;7.4, as set forth in Exhibit&nbsp;8.1. To the extent permitted by law such allocation of the Aggregate Purchase Price shall be binding for
Seller and Purchaser for all aspects including but not limited to tax filings. The Aggregate Purchase Price less any sums held back pursuant to Sections 8.2(b) or 12.5 shall be paid to Seller by
transfer of immediately available funds and free of wire transfer charges and transfer taxes to: </FONT></DD></DL>
</UL>
</UL>
<BR>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>Account</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="65%"><FONT SIZE=2>BASF AG</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>Bank</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="65%"><FONT SIZE=2>Citibank, New York</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>SWIFT Code</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="65%"><FONT SIZE=2>CITIUS33</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>ABA No.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="65%"><FONT SIZE=2>021000089</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="13%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="17%"><FONT SIZE=2>Account No.</FONT></TD>
<TD WIDTH="2%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="65%"><FONT SIZE=2>***</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=4,SEQ=4,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=601680,FOLIO='4',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_5"> </A>
<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>8.2</FONT></DT><DD><FONT SIZE=2>(a)
The Aggregate Purchase Price shall be adjusted as provided for in Sections 9 and 10 below or as a result of a claim for indemnification
pursuant to Sections 15, 18 and 21 below. </FONT></DD></DL>
</UL>
<UL>
<UL>

<P><FONT SIZE=2>(b)
Purchaser shall withhold *** (the "Uetersen Amount") from the Aggregate Purchase Price paid at the Closing and shall hold the Uetersen Amount in escrow until such time as Seller shall have
delivered to Purchaser satisfactory evidence of the full and unconditional termination of (i)&nbsp;the License Agreement (</FONT><FONT SIZE=2><I>Lizenzvertrag</I></FONT><FONT SIZE=2>) (the
"Uetersen License"), regarding the marketing and sale of Pancreatin, to be executed by Knoll AG and Nordmark Arzneimittel GmbH&nbsp;&amp; CO. KG pursuant to the Master Agreement regarding the
acquisition of the Uetersen factory of Knoll AG (</FONT><FONT SIZE=2><I>Rahmenvertrag ueber den Erwerb der Betriebsstaette Werk Uetersen der Knoll AG</I></FONT><FONT SIZE=2>) between Knoll AG and
Dr.&nbsp;Peter Tonne, and (ii)&nbsp;Knoll AG's obligation to execute and deliver such Uetersen License; provided, that if the Uetersen License and such obligation are not so terminated within ***
after Closing, Purchaser shall retain the Uetersen Amount and such Uetersen Amount will constitute a reduction of the Aggregate Purchase Price. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>8.3</FONT></DT><DD><FONT SIZE=2>(a)
The parties acknowledge that the Aggregate Purchase Price does not reflect any amounts to be paid in respect of the computations to be made
pursuant to Sections 9 and 10, and Exhibit&nbsp;7.4 hereof. </FONT></DD></DL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>(b)
If the Provisional Knoll India Base Amount exceeds the Knoll India Base Amount (the "Knoll India Base Amount Overallocation"), an amount equal to the Knoll India Base Amount Overallocation shall
be allocated to such other Shares (other than the BASF Knoll India Shares) or assets of the Companies (other than Knoll India) in such manner as Purchaser and Seller shall mutually agree. If the Knoll
India Base Amount exceeds the Provisional Knoll India Base Amount (the "Knoll India Base Amount Underallocation"), an amount equal to the Knoll India Base Amount Underallocation shall reduce the
amount allocated to the BASF Knoll India Shares. </FONT></P>

<P><FONT SIZE=2>The
"Non-Indian Purchase Price" shall be equal to (a)&nbsp;the Aggregate Purchase Price, less (b)&nbsp;the Knoll India Base Amount. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.5.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;9, Non-Hokuriku Purchase Price Adjustment" is hereby retitled "Section&nbsp;9, Non-Indian
Purchase Price Adjustment" and amended by amending and restating such section in its entirety as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>9.1</FONT></DT><DD><FONT SIZE=2>The
Non-Indian Purchase Price shall be adjusted as follows: </FONT>
<DL compact>
<DT><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2>As
of September&nbsp;30, 2000, the net asset value of the BASF Pharmaceutical Business amounts to *** (such amount, </FONT></DD></DL>
</DD></DL>
</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=5,SEQ=5,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=911191,FOLIO='5',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_6"> </A>
<UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>net
of the Knoll India Reference Net Asset Value, being hereinafter referred to as "Reference Net Asset Value"). The Reference Net Asset Value has been determined on the basis of the unaudited
proforma balance sheet contained in the attached Exhibit&nbsp;9.1(a) in item&nbsp;3.2 thereof taking into account adjustments, as shown in Exhibit&nbsp;9.1(b) by the elimination of
(i)&nbsp;Cash, Financial Debt, deferred Taxes and Accrued Taxes as shown in Exhibit&nbsp;9.1(a), (ii)&nbsp;deferrals shown in Exhibit&nbsp;9.1(a) as miscellaneous liabilities related to
expenses of Seller allocated to the BASF Pharmaceutical Business; and (iii)&nbsp;other current assets as shown in Exhibit&nbsp;9.1(a) related to one-time payments of American Home Products to
Seller with regard to a certain patent ("Enbrel"). Notwithstanding anything to the contrary set forth in this Section&nbsp;9.1, Exhibit&nbsp;9.1(a) or Exhibit&nbsp;9.1(b), Section&nbsp;21.4
shall govern to the exclusion of this Section&nbsp;9.1 with respect to the calculations described therein. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2>If
the net asset value of the BASF Pharmaceutical Business as of the Closing (net of the Knoll India Closing Net Asset Values) as determined in
accordance with the principles set forth in Section&nbsp;10 below and as shown on the Final Closing Net Asset Value Statement (hereinafter referred to as the ("Closing Net Asset Value") is less than
the Reference Net Asset Value, Seller shall pay to Purchaser the amount by which the Closing Net Asset Value is less than the Reference Net Asset Value.
<BR><BR></FONT></DD><DT><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2>If
the Closing Net Asset Value exceeds the Reference Net Asset Value, Purchaser shall pay to Seller in addition to the amounts required to be paid
pursuant to Section&nbsp;8.1 the amount by which the Closing Net Asset Value exceeds the Reference Net Asset Value. </FONT></DD></DL>
<BR>
</UL>
<DL compact>
<DT><FONT SIZE=2>9.2</FONT></DT><DD><FONT SIZE=2>The
amount determined in accordance with Section&nbsp;9.1 above shall be paid by Seller or Purchaser, as the case may be in USD, together with
any accrued interest at a rate of six percent per annum as of the Closing within 5 working days after the Closing Net Asset Value Statement has become final in accordance with Section&nbsp;10.5
hereof in immediately available funds free of wire transfer charges and transfer taxes to the bank account set forth in Section&nbsp;8.1 above, if payment is to be made to Seller, and to Citibank,
N.A., New York, New York (ABA #021000089) for credit to Abbott Laboratories *** if payment is to be made to Purchaser. Any credit to Purchaser shall be made in USD at the spot exchange rate in effect
at two business days prior to the date of payment. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.6.&nbsp;&nbsp;Sections
10.1 and 10.2 of the Purchase Agreement are hereby amended by amending and restating such sections in their entirety as follows: </FONT></P>

<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=6,SEQ=6,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=941030,FOLIO='6',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_7"> </A>
<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>10.1</FONT></DT><DD><FONT SIZE=2>For
the purpose of determining the amount of the purchase price adjustment, if any, pursuant to Section&nbsp;9 above, Seller shall deliver to
Purchaser as promptly as practicable (but in any event no more than 45&nbsp;days) after the Closing an audited consolidated balance sheet and statement of changes in shareholder's equity of the
Companies as of the Closing (the "Closing Balance Sheet") and the Closing Net Asset Value Statement, each prepared by Seller and audited by Deloitte&nbsp;&amp; Touche GmbH ("Seller's Auditors")
(hereinafter referred to as "Closing Net Asset Value Statement") reflecting the Closing Net Asset Value, together with the report of Seller's Auditors thereon ("Auditor's Report"). The Closing Balance
Sheet and the statement of changes in shareholder's equity included in the Auditor's Report shall be prepared in accordance with the Report Principles (as defined in Section&nbsp;13.20) as of the
Closing Date, and prepared and consolidated in a manner consistent with Exhibit&nbsp;9.1(a). The Closing Net Asset Value Statement included in the Auditor's Report shall be prepared on the basis of,
and derived from, the balance sheet contained in the Closing Balance Sheet, and adjusted in a manner consistent with Exhibit&nbsp;9.1(b), and further adjusted in accordance with the principles set
forth in Exhibit&nbsp;10.1 hereto; provided however, that (a)&nbsp;the value of any Cash of Hokuriku (or intercompany item or receivable in respect of Cash of Hokuriku) to be set forth on the
Final Hokuriku Net Asset Value Statement shall not exceed ***, (b)&nbsp;the Closing Balance Sheet shall not reflect any cash of the Companies to be paid after Closing by way of dividend or
distribution to which Purchaser shall not be entitled, (c)&nbsp;no value shall be included on the Closing Balance Sheet for the Excluded Inventories (as hereinafter defined), and (d)&nbsp;the
Closing Balance Sheet shall include as an asset an adjustment of U.S. $321,000 to the extent such adjustment has been paid prior to Closing. The audit of the Closing Balance Sheet shall include a
physical count and valuation of the Companies' inventory. The Auditor's Report shall provide at least as much detail by financial statement line item as is included in Exhibit&nbsp;9.1(a).
Intercompany Obligations shall be dealt with as provided in Section&nbsp;19; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that
the Closing Net Asset Value Statement shall reflect the amounts payable by the Companies and the amounts payable by Seller pursuant to the Agreement set forth on Exhibit&nbsp;19.3. Notwithstanding
anything to the contrary set forth in this Section&nbsp;10.1, Exhibit&nbsp;7.4 shall govern the calculation of the Knoll India Net Asset Value described therein.
<BR><BR></FONT></DD><DT><FONT SIZE=2>10.2</FONT></DT><DD><FONT SIZE=2>To
the extent that the Closing Net Asset Value Statement arrives at a Closing Net Asset Value resulting in an adjustment of the Non-Indian
Purchase Price pursuant to Section&nbsp;9, the Closing Net Asset Value Statement must also state how the amount by which the Non-Indian Purchase Price, as so adjusted, should be allocated. The
parties acknowledge and agree that (a)&nbsp;the Knoll India Purchase Price reflects the value of any additional net assets that may be attributable to Knoll India and that no additional allocation
to Knoll India shall be made in excess of </FONT></DD></DL>
</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=7,SEQ=7,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=995238,FOLIO='7',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_8"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>the
Knoll India Purchase Price as calculated pursuant to Section&nbsp;7.4, (b)&nbsp;no additional allocation to Knoll Pharmaceuticals&nbsp;Ltd., a Pakistan corporation, shall be made in excess
of the amount set forth on Exhibit&nbsp;8.1 for such entity, and (c)&nbsp;no additional amount shall be allocated to BASF Pharmaceutical Corp. on account of its holdings in Hokuriku. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.7.&nbsp;&nbsp;Section&nbsp;11.1.1
of the Purchase Agreement is hereby amended by adding the following subsections (d)&nbsp;and (e): </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>d)</FONT></DT><DD><FONT SIZE=2>Seller
shall have completed the Hokuriku Share transfer procedures described in Exhibit&nbsp;11.1.1(d).
<BR><BR></FONT></DD><DT><FONT SIZE=2>e)</FONT></DT><DD><FONT SIZE=2>Seller
shall have completed the transfer procedures relating to Knoll Pharmaceuticals&nbsp;Ltd. and Knoll International&nbsp;Ltd. described in
paragraphs 1(a) and 2 of Exhibit&nbsp;11.1.1(e). </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.8.&nbsp;&nbsp;Section&nbsp;12.2
of the Purchase Agreement is hereby amended by adding the following subsection (d): </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>d.</FONT></DT><DD><FONT SIZE=2>a
duly executed sales and transfer contract transferring from the Companies to Seller or its Affiliates the entities set forth on
Exhibit&nbsp;12.2(d). </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.9&nbsp;&nbsp;Section&nbsp;12.5
is hereby amended by adding the following to the end of such Section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>The
parties acknowledge that the shares in the Companies described on Exhibit&nbsp;12.5 shall be Shares subject to this Section&nbsp;12.5. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.10.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;13, Representations of Seller" is hereby amended by adding the following Section&nbsp;13.29: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>13.29&nbsp;(I)&nbsp;&nbsp;The
entities described below have been held, directly or indirectly, 100% (66.67% as to Hokuriku) by Seller in an uninterrupted chain of title as described
below: </FONT></P>

<DL compact>
<DT><FONT SIZE=2>(a)</FONT></DT><DD><FONT SIZE=2><I>Knoll AG</I></FONT>
<DL compact>
<DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000 to November&nbsp;27, 2000, Seller owned directly 100% of the issued and outstanding shares of capital
stock of Knoll AG;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>On
November&nbsp;27, 2000, Seller transferred a 94% interest in Knoll AG to BASF Pharma Holding GmbH, a wholly owned direct subsidiary of
Seller; </FONT></DD></DL>
</DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=8,SEQ=8,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=1029846,FOLIO='8',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_9"> </A>
<UL>
<UL>
<UL>
<UL>
</UL>
<DL compact>
<DT><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>Seller
and BASF Pharma Holding GmbH will until Closing continue to own directly 6 and 94&nbsp;percent, respectively, of the issued and
outstanding shares of Knoll AG;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iv)</FONT></DT><DD><FONT SIZE=2>Seller
has, since prior to January&nbsp;1, 2000 owned, and Seller will continue until the Closing to own, directly 100% of the equity interests
(Gesch&auml;ftsanteile) of BASF Pharma Holding GmbH; </FONT></DD></DL>
</UL>
<DL compact>
<DT><FONT SIZE=2>(b)</FONT></DT><DD><FONT SIZE=2><I>Lupharma and Transpharm</I></FONT>
<DL compact>
<DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000 to July&nbsp;1, 2000, Knoll AG owned directly 100% of the equity interests
(Gesch&auml;ftsanteile) of each of Lupharma and Transpharm;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;1, 2000, Knoll AG transferred to Seller all of Knoll AG's right, title and interest in and to the equity interests
(Gesch&auml;ftsanteile) of each of Lupharma and Transpharm, being in each case 100% of the equity interests (Gesch&auml;ftsanteile) thereof;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;1, 2000, immediately upon having acquired all of Knoll AG's right, title and interest in and to the equity interests
(Gesch&auml;ftsanteile) of each of Lupharma and Transpharm, Seller transferred to BASF Pharma Holding GmbH all of Seller's right, title and interest in and to the equity interests
(Gesch&auml;ftsanteile) of each of Lupharma and Transpharm, being in each case 100% of the equity interests (Gesch&auml;ftsanteile) thereof;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iv)</FONT></DT><DD><FONT SIZE=2>BASF
Pharma Holding GmbH has since July&nbsp;1, 2000 owned, and BASF Pharma Holding GmbH will continue until the Closing to own, directly 100%
of the equity interests (Gesch&auml;ftsanteile) of each of Lupharma and Transpharm; </FONT></DD></DL>
</DD></DL>
<DL compact>
<DT><FONT SIZE=2>(c)</FONT></DT><DD><FONT SIZE=2><I>Hokuriku</I></FONT>
<DL compact>
<DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>Since
January&nbsp;1, 2000, Seller's interest in the issued and outstanding shares in Hokuriku has been owned as set forth in
Exhibit&nbsp;13.29;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>Lupharma
has acquired by an agreement dated July&nbsp;1, 2000, and Lupharma will continue until the completion of the transfers contemplated by
Exhibit&nbsp;11.1.1(d) to own, directly 14,616,000 shares in Hokuriku;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>Transpharm
has acquired by an agreement dated July&nbsp;1, 2000, and Transpharm will continue until the completion of the transfers </FONT></DD></DL>
</DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=9,SEQ=9,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=834371,FOLIO='9',FILE='DISK016:[01CHI1.01CHI1831]KC1831A.;21',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_10"> </A>
<UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>contemplated
by Exhibit&nbsp;11.1.1(d) to own, directly 14,616,000 shares in Hokuriku; </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>(iv)</FONT></DT><DD><FONT SIZE=2>Immediately
prior to Closing, the transfers contemplated by Exhibit&nbsp;11.1.1(d) shall have been completed; </FONT></DD></DL>
<BR>
</UL>
<DL compact>
<DT><FONT SIZE=2>(d)</FONT></DT><DD><FONT SIZE=2><I>Knoll Pharmaceutical Company</I></FONT><FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT><FONT SIZE=2>(i)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000, BASFin has owned, and BASFin will continue until the Closing to own, directly 100% of the issued and
outstanding shares of capital stock of BASF Corporation;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(ii)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000 to July&nbsp;31, 2000, BASF Corporation owned directly 100% of the issued and outstanding shares of
capital stock of BASF Capital Corporation;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iii)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000 to July&nbsp;31, 2000, BASF Capital Corporation owned directly 100% of the issued and outstanding shares
of capital stock of Knoll Pharmaceutical Company;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(iv)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;31, 2000, BASF Capital Corporation was merged into BASF Corporation, as a result of which Knoll Pharmaceutical Company became a
wholly owned direct subsidiary of BASF Corporation;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(v)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;31, 2000, BASF Corporation transferred to BASF Pharmaceutical Corporation all of the issued and outstanding shares of capital stock
of Knoll Pharmaceutical Company, as a result of which Knoll Pharmaceutical Company became a wholly owned direct subsidiary of BASF Pharmaceutical Corporation;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(vi)</FONT></DT><DD><FONT SIZE=2>BASF
Pharmaceutical Corporation has since July&nbsp;31, 2000 owned, and BASF Pharmaceutical Corporation will continue until the Closing to own,
directly 100% of the issued and outstanding shares of capital stock of Knoll Pharmaceutical Company;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(vii)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;31, 2000, BASF Corporation transferred to BASFin Corporation all of the issued and outstanding shares of capital stock of BASF
Pharmaceutical Corporation, as a result of which BASF Pharmaceutical Corporation became a wholly owned direct subsidiary of BASFin Corporation;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(viii)</FONT></DT><DD><FONT SIZE=2>Since
prior to January&nbsp;1, 2000, Seller owned, and will continue until the Closing to own, directly 100% of the issued and outstanding
shares of capital stock of BASFin Corporation; </FONT></DD></DL>
</DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=10,SEQ=10,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=228746,FOLIO='10',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_11"> </A>
<UL>
<UL>
<UL>
<UL>
</UL>
<DL compact>
<DT><FONT SIZE=2>(ix)</FONT></DT><DD><FONT SIZE=2>On
July&nbsp;31, 2000, BASFin Corporation transferred to Seller all of the issued and outstanding shares of capital stock of BASF
Pharmaceutical Corporation, as a result of which BASF Pharmaceutical Corporation became a wholly owned direct subsidiary of Seller;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(x)</FONT></DT><DD><FONT SIZE=2>On
November&nbsp;27, 2000, Seller transferred to BASF Pharma Holding GmbH all of the issued and outstanding shares of capital stock of BASF
Pharmaceutical Corporation, as a result of which BASF Pharmaceutical Corporation became a wholly owned direct subsidiary of BASF Pharma Holding GmbH;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(xi)</FONT></DT><DD><FONT SIZE=2>On
November&nbsp;27, 2000, BASF Pharma Holding GmbH transferred to Lupharma all of the issued and outstanding shares of capital stock of BASF
Pharmaceutical Corporation, as a result of which BASF Pharmaceutical Corporation became a wholly owned direct subsidiary of Lupharma;
<BR><BR></FONT></DD><DT><FONT SIZE=2>(xii)</FONT></DT><DD><FONT SIZE=2>During
the period from November, 2000 to the date hereof, Lupharma GmbH will continue until the Closing to own directly 100% of the issued and
outstanding shares of capital stock of BASF Pharmaceutical Corporation; </FONT></DD></DL>
</UL>
</UL>
</UL>
<UL>
<UL>

<P><FONT SIZE=2>(II)&nbsp;&nbsp;On
February&nbsp;27, 2001, Knoll AG transferred 18,062,659 quotas of Knoll Produtos Quimicos e Farmaceuticos&nbsp;Ltda., which represent 99.999% of its share capital, to
Lupharma. On that same date, Knoll Produtos Quimicos e Farmaceuticos&nbsp;Ltda. amended its Articles of Association to reflect this transfer. Further on that same date, the amendment of the Articles
of Association was filed with the Commercial Registry of Rio de Janeiro and the transfer of the quotas was recorded in the books and records of Knoll AG and Lupharma. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.11.&nbsp;&nbsp;Section&nbsp;15.1(I)&nbsp;of
the Purchase Agreement is hereby amended by adding the following subsections (d), (e), (f), and (g): </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>d)</FONT></DT><DD><FONT SIZE=2>***
<BR><BR></FONT></DD><DT><FONT SIZE=2>e)</FONT></DT><DD><FONT SIZE=2>(i)&nbsp;The
failure of the representations and warranties set forth in Section&nbsp;13.1 to be true and correct with respect to ***, the
failure by *** to have prepared </FONT></DD></DL>
</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=11,SEQ=11,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=460383,FOLIO='11',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_12"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>financial
statements as required by law and any action by the Purchaser Group or *** after Closing necessary to render such representations and warranties true and correct, and (ii)&nbsp;the sale by
*** of its assets to a party designated by Purchaser or the liquidation of ***, including any and all costs, Taxes, filing, registration and other fees, and expenses (including reasonable attorneys'
and accountants' fees, liabilities to creditors, and any fines or penalties) arising out of or relating thereto or reasonably incurred to bring *** into compliance with *** laws and regulations, to
the extent such compliance is a condition to the liquidation of ***; </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>f)</FONT></DT><DD><FONT SIZE=2>Any
Taxes, including stamp taxes, transfer taxes and VAT, arising from or related to (i)&nbsp;the shares of Knoll Pharma&nbsp;Ltd. and
Knoll&nbsp;Ltd. and/or (ii)&nbsp;the sale, transfer or other disposition of any Discontinued Businesses or any of the entities or businesses described on Exhibit&nbsp;12.2(d), whenever effected;
and
<BR><BR></FONT></DD><DT><FONT SIZE=2>g)</FONT></DT><DD><FONT SIZE=2>Knoll
Sant&eacute; Active S.A. ("Knoll Sant&eacute;") that the Purchaser Group would not have incurred had Knoll
Sant&eacute; not been acquired, directly or indirectly, by Purchaser, including any liabilities, Taxes, costs, filing, registration and other fees, and expenses (including reasonable
attorneys' and accountants' fees) arising
out of or related to Knoll Sant&eacute;, its business or operations prior to Closing, or its liquidation, winding up or dissolution. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.12.&nbsp;&nbsp;Section&nbsp;15.4
of the Purchase Agreement is hereby amended by amending and restating such section in its entirety as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>15.4</FONT></DT><DD><FONT SIZE=2>The
limitation of the liability of Seller set forth in Sections 15.2 and 15.3 above shall not apply in case of a violation of any Representation
made in Sections 13.1 through 13.4, Section&nbsp;13.9, Section&nbsp;13.15.3(a), and Section&nbsp;13.29. In this case, the liability of Seller shall be limited to the amount of the Aggregate
Purchase Price as adjusted pursuant to Section&nbsp;9. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.13.&nbsp;&nbsp;Section&nbsp;15.8(a)
of the Purchase Agreement is hereby amended by amending and restating such section in its entirety as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>a)</FONT></DT><DD><FONT SIZE=2>claims
pursuant to Sections 13.1 through 13.4, 13.9, 13.15.3(a), and 13.29, and claims pursuant to Sections 13.13 and 13.14 which are based on a
defect of title, shall be subject to a survival period of ***; </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.14.&nbsp;&nbsp;Section&nbsp;19.3
of the Purchase Agreement is hereby amended by inserting the following phrase at the beginning of such section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Except
as the parties may otherwise agree as set forth on Exhibit&nbsp;19.3, </FONT></P>

</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=12,SEQ=12,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=160686,FOLIO='12',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_13"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;2.15.&nbsp;&nbsp;Section&nbsp;21.1 of the Purchase Agreement is hereby amended by adding the following sentence at the end of such section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>To
the extent not otherwise indemnifiable under any other indemnity provision of this Agreement, Seller shall indemnify and hold harmless Purchaser and each of its Affiliates (including the Companies)
from and against any and all Damages (including, without limitation, costs and expenses of litigation and reasonable attorneys' fees and expenses for physical delivery of shares) arising out of or
related to claims asserted under Seller's stock option programs or any stock purchase plan of Seller or its Affiliates against Purchaser or any of its Affiliates (including the Companies). </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.16.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;24, Conduct of Business prior to Closing" is hereby amended by adding the following Sections
24.14, 24.15, 24.16, 24.17 and 24.18: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.14</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Prior to the Closing, Seller shall cause (a)&nbsp;the Hokuriku Shares owned by it to be transferred to KPC as described on Exhibit&nbsp;11.1.1(d), and (b)&nbsp;the Shares of the Indian entities described on Exhibit&nbsp;11.1.1(e) to be transferred to
Seller's new companies as described therein.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.15</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
If there are any Shares not transferred at Closing pursuant to Section&nbsp;12.5, including the Shares of Lupharma UK Holding II,&nbsp;Ltd., the rights of Purchaser as described in Section&nbsp;24.5(a) shall continue post-Closing for purposes of
determining Seller's compliance with the terms of this Purchase Agreement, including, without limitation, compliance with the terms in Sections 12.5 and 24.8. Such rights shall terminate when all such Shares are transferred in accordance with Section
&nbsp;12.5.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.16</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Seller shall, without further consideration and at no additional cost to Purchaser in excess of those costs that the Companies would have incurred had they remained Affiliates of Seller (such costs to be calculated on a basis consistent with the pro
forma financial statements provided to Purchaser in the London data room in November&nbsp;2000, or to Purchaser during the November&nbsp;2000 Seller management presentation), take such acts, or cause such acts to be taken, as necessary to ensure
uninterrupted and lawful use by the Companies worldwide from and after the Closing Date of all information technology ("IT"), software, data and IT related equipment and hardware, including routers and telecommunications and data equipment
(collectively, "IT Rights") utilized by the Companies in the conduct of their respective businesses. Such acts shall include, if necessary to insure such uninterrupted and lawful use, the valid transfer of Seller's or its Affiliates' existing IT
Rights, including, without limitation, any rights pertaining to any IT or software customized by Seller and/or its Affiliates, the separate procurement of such IT Rights in the name of and for the benefit of the Companies or the valid transfer of
copies of any</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="RIGHT"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=13,SEQ=13,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=871754,FOLIO='13',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_14"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2>Seller-owned software (including source codes and documentation) (the "IT/Software Licenses"). Such IT/Software Licenses include, without limitation, the following:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%" ALIGN="CENTER"><FONT SIZE=2><BR>
***</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.17</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
Seller (a)&nbsp;shall procure that, effective no later than ***, any license relating to Pharmaceutical Products and granted by it or any of its Affiliates to ***, shall be terminated or shall expire, including any license to use the "TET" technology
and, (b)&nbsp;hereby undertakes not to exercise or obtain any benefit of any right of first refusal, first offer or similar rights on developments, research or products arising from ***, the research, development, importation, use, registration,
manufacture, distribution or sale of which would violate or be inconsistent with Section&nbsp;27.1.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.18</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
The parties acknowledge that Purchaser shall not acquire certain inventories of the Companies with a book value of up to $30&nbsp;million (the "Excluded Inventories"). No later than twenty (20)&nbsp;business days after the Closing, Purchaser shall
deliver to Seller a statement describing the Excluded Inventories ("Excluded Inventories Notification"). Seller shall, at its sole cost and expense (a)&nbsp;remove from the Companies' premises all of the Excluded Inventories, and (b)&nbsp;destroy of
the Excluded Inventories in<BR></FONT>
</TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->

<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=14,SEQ=14,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=78459,FOLIO='14',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_15"> </A>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2>compliance with applicable law ("Inventory Destruction"), no later than ten (10)&nbsp;business days after Seller's receipt of the Excluded Inventories Notification or such later date as may be necessary to comply with
applicable laws governing such Destruction (the "Destruction Date"). Seller shall certify to Purchaser in writing that the Inventories Destruction shall have been completed in accordance with this Section&nbsp;24.18 no later than ten (10)
&nbsp;business days after the Destruction Date. If the book value of the Excluded Inventories is less than $ 30&nbsp;million, Seller shall pay to Purchaser, no later than 10 business days after Seller's receipt of the Excluded Inventories
Notification, an amount in cash by immediately available same day funds equal to the difference between $30&nbsp;million and such book value.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="16%" ALIGN="RIGHT"><FONT SIZE=2><BR>
24.19</FONT></TD>
<TD WIDTH="1%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="83%"><FONT SIZE=2><BR>
After the Closing, Seller shall continue to prosecute, at its own expense and with its own counsel, the EBEWE Insurance Claims. Each of Purchaser and Seller shall pay to the other party 50% of any proceeds or recovery from the EBEWE Insurance Claims
(net of expenses and any Taxes arising in connection therewith) that it may receive no later than 5 business days after receipt by Purchaser or Seller (as the case may be) of such proceeds or recovery. "EBEWE Insurance Claims" shall mean claim No.
&nbsp;C 00006292 asserted by Seller on behalf of EBEWE Arzneimittel GmbH ("EBEWE") against American International Group,&nbsp;Inc. (AIG) under Policy No. Y10FID2100 in the approximate amount of 28,400,000 Euro, relating to losses incurred by EBEWE on
account of unauthorized forward currency exchange transactions undertaken by former employees of EBEWE with funds of EBEWE.</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.17&nbsp;&nbsp;Section&nbsp;24.8
of the Purchase Agreement is hereby amended by adding the following sentence to the end of such Section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>With
respect to the Shares that are not transferred at Closing (the "Excluded Companies"), Seller covenants that it will, and will cause the Excluded Companies to: (a)&nbsp;provide Purchaser with a
contact person of each of such Companies who shall coordinate any procedures with respect to such Companies for financial reporting or the transfer of such Companies following the Closing,
(b)&nbsp;permit Purchaser and its representatives to have reasonable access to the assets, employees, books and records of such Companies, and shall furnish or cause to be furnished to Purchaser
such financial, tax, regulatory, R&amp;D and operating data and other available information with respect to such Companies as Purchaser may from time to time request or that may otherwise be legally
required by Purchaser, and (c)&nbsp;upon the transfer of the Shares of each such Excluded Company to Purchaser, remit all earnings of such Company through the date of such transfer as soon as
practicable (but no later than five (5)&nbsp;business days) after the date of such transfer, together with interest thereon at a rate of six percent per annum from the Closing through the date on
which such earnings are paid to the Company. </FONT></P>

</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=15,SEQ=15,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=1010015,FOLIO='15',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_16"> </A>
<UL>
<UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.18.&nbsp;&nbsp;Section&nbsp;25
of the Purchase Agreement is hereby amended by amending and restating Sections 25.2, 25.3 and 25.4 in their entirety and by adding a new
Section&nbsp;25.5, as follows: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>25.2</FONT></DT><DD><FONT SIZE=2>Seller
hereby grants to Purchaser and Purchaser's Affiliates including the Companies, with respect to Seller Shared Substance Related Patents an
irrevocable, exclusive fully paid-up license for the life of the respective patent, with the right to grant sublicenses, in the Pharmaceutical Field and the Pharmachemical Field.
<BR><BR></FONT></DD><DT><FONT SIZE=2>25.3</FONT></DT><DD><FONT SIZE=2>Purchaser
hereby grants to Seller with respect to the Shared Substance Related Patents an irrevocable, exclusive fully paid-up license for the
life of the respective patent, with the right to grant sublicenses, outside of the Pharmaceutical Field and the Pharmachemical Field.
<BR><BR></FONT></DD><DT><FONT SIZE=2>25.4</FONT></DT><DD><FONT SIZE=2>Except
as otherwise agreed by the parties, the following procedures will govern Shared Substances that are located on the premises of one party
but that are not physically present already in the compound collection of the other party. Either Purchaser or Seller may request samples of Shared Substances from the other party, subject to the
following: </FONT></DD></DL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>(a)&nbsp;&nbsp;The
number of samples of different compounds requested by a party shall not exceed 20,000 in the aggregate; </FONT></P>

<P><FONT SIZE=2>(b)&nbsp;&nbsp;Each
solid sample request must be for a physical quantity of 20 milligrams or less; </FONT></P>

<P><FONT SIZE=2>(c)&nbsp;&nbsp;No
party shall be required to provide any solid sample of Shared Substances if such party has less than 70 milligrams of such Shared Substances remaining in such party's compound
library; and </FONT></P>

<P><FONT SIZE=2>(d)&nbsp;&nbsp;No
party shall be required to provide any sample requested after September&nbsp;3, 2002. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>25.5</FONT></DT><DD><FONT SIZE=2>The
parties acknowledge that Seller owns certain patents relating to certain inactive ingredients that are being supplied by Seller or one of its
Affiliates to the Companies, commonly known as "excipients" ("Excipients"). Seller agrees that, with respect to Excipients that are the basis of, or included in, any product registrations of any of
the Companies ("Covered Excipients"), (a)&nbsp;Seller shall, and shall cause its Affiliates to, continue to supply the Companies with their requirements of Covered Excipients on terms and conditions
generally offered to Seller's comparable customers, and (b)&nbsp;if Seller and its Affiliates cease to manufacture and sell any Covered Excipients, Seller shall (i)&nbsp;provide Purchaser with not
less than 12&nbsp;months prior written notice of such </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=16,SEQ=16,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=802557,FOLIO='16',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_17"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>cessation,
and (ii)&nbsp;grant the Companies an irrevocable, non-exclusive, paid-up license for the life of the respective patent, with the right to grant sublicenses, to make, have made and use the
Covered Excipients to produce any of the Companies' products in the Pharmaceutical Field. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.19.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;26, Conduct and Litigation" is hereby amended as follows: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;Section&nbsp;26.1(i)&nbsp;of
the Purchase Agreement is hereby amended by inserting the phrase "to the extent" immediately preceding the existing phrase "based
upon, arising out of, or related to." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;Section&nbsp;26.1(iv)&nbsp;of
the Purchase Agreement is hereby amended by replacing the existing term "26(a)(i)" with the term "26.1(i)." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;Section&nbsp;26.1
of the Purchase Agreement is hereby amended by adding the following sentence at the end of such section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Loss,
liability, damage and expenses covered by this Section&nbsp;26 shall include, without limitation, any expenses arising from the provision of free product by KPC, net of any reserve on the
Closing Date Balance Sheet for any such product. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;Section&nbsp;26.2
of the Purchase Agreement is hereby amended by inserting the term "hereafter" immediately preceding the existing phrase "commenced against it"
in the first sentence of such section. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;Section&nbsp;26.3
of the Purchase Agreement is hereby amended by inserting the phrase "Section&nbsp;26.2 above and" immediately preceding the existing phrase
"Section&nbsp;26.4" in the first sentence of such section. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;Section&nbsp;26.6
of the Purchase Agreement is hereby amended and restated in its entirety as follows: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Insurance
Proceeds and Settlement Amounts. Seller shall be entitled to all </FONT><FONT SIZE=2><I>In re Synthroid</I></FONT><FONT SIZE=2>&reg; </FONT><FONT SIZE=2><I>Marketing Litigation  </I></FONT><FONT SIZE=2>Settlement Amounts. In addition, if and to the
extent that Seller prosecutes, at its own expense and with its own counsel, the Insurance Litigation, Seller shall be entitled to
any proceeds or recovery arising from or out of the Insurance Litigation. Purchaser hereby assigns any and all rights, claims and/or interests in the Insurance Litigation to Seller, including
authorizing Seller to sue, continue suit, prosecute, receive and retain any and all recoveries or proceeds in or from the Insurance Litigation without limitation in the name of Knoll Pharmaceutical
Company, all and with the same force and effect as if Knoll Pharmaceutical Company and/or any and all predecessors and/or successors to Knoll Pharmaceutical Company had done so. </FONT></P>

</UL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=17,SEQ=17,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=873636,FOLIO='17',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_18"> </A>
<UL>
<UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;Section&nbsp;26.7(i)&nbsp;of
the Purchase Agreement is hereby amended by deleting the existing term "and" immediately preceding the existing term "(3)" and by
adding the following phrase at the end of such section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>;
(4) the dismissal of </FONT><FONT SIZE=2><I>RxD Pharmacies,&nbsp;Inc. v. BASF, et al.</I></FONT><FONT SIZE=2>, No.&nbsp;98CV-5560, United States District Court for the Eastern District of
Pennsylvania; (5)&nbsp;</FONT><FONT SIZE=2><I>In the Matter of Coordinated Proceedings Special Title, Pharmaceutical Cases I, II and III</I></FONT><FONT SIZE=2>, J.C.C.P. Nos. 2969, 2971 and 2972
in the Superior Court of California; and (6)&nbsp;any settlement or similar agreements entered into in connection therewith, including the Master Agreement of Settlement and Release entered into by
Knoll on February&nbsp;1, 1999. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;Section&nbsp;26.7(ii)&nbsp;of
the Purchase Agreement is hereby amended by amending and restating such section in its entirety as follows: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>(ii)&nbsp;"Section&nbsp;26
Conduct" shall mean the conduct alleged, or conduct substantially similar to that alleged, in the Section&nbsp;26 Litigation, and which in each case occurs
prior to Closing; </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;Section&nbsp;26.7
(iii)&nbsp;of the Purchase Agreement is hereby amended by adding the following phrase at the end of such Section and immediately before the
existing term "and": </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>and
any policies in excess thereof that were issued to Knoll Pharmaceutical Company or its predecessors prior to the Closing. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.20.&nbsp;&nbsp;Section&nbsp;27.2
of the Purchase Agreement is hereby amended by adding the following sentence at the end of such section: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>Further,
subject to the following proviso, the preceding paragraph shall not prevent Seller from maintaining its equity ownership interest in the joint venture company ***; </FONT> <FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, that (x)&nbsp;any such
equity ownership interest percentage shall be not more than ***, (y)&nbsp;such equity ownership interest shall be
for financial investment purposes only and shall not extend, directly or indirectly, to (1)&nbsp;any other arrangements, contracts, revenue sharing, licensing or right of first refusal, first offer
or similar rights on developments, research or products arising from ***, the research, development, importation, use registration, manufacture, distribution or sale of which would violate or be
inconsistent with Section&nbsp;27.1, or (2)&nbsp;other opportunities of any kind with such joint venture company in any manner that would otherwise violate or be inconsistent with
Section&nbsp;27.1, and (z)&nbsp;no assets, properties, rights or interest, including Patents or Intellectual Property, of any of the Companies or the BASF Pharmaceutical Business shall be made
available, provided or licensed to or used </FONT></P>

</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">
<DL compact>
<DT><FONT SIZE=2>***</FONT></DT><DD><FONT SIZE=2>Confidential
information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></DD></DL>
<P ALIGN="RIGHT"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=18,SEQ=18,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=446208,FOLIO='18',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_19"> </A>
<UL>

<P><FONT SIZE=2>by
such joint venture company, including, without limitation, through any license of "TET" technology. </FONT></P>

</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.21.&nbsp;&nbsp;The
section of the Purchase Agreement entitled "Section&nbsp;27, Non-Compete Covenant" is hereby amended by adding the following Section&nbsp;27.3: </FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>27.3</FONT></DT><DD><FONT SIZE=2>Notwithstanding
anything in Sections 27.1 or 27.2 to the contrary, the operation of the restrictions in such sections in Turkey shall be for a
period of *** following the Closing. </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.22.&nbsp;&nbsp;Exhibit&nbsp;4.2(b)
to the Purchase Agreement is hereby deleted. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.23.&nbsp;&nbsp;Exhibits
5.1 and 5.2 to the Purchase Agreement are hereby amended as follows: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;Exhibit&nbsp;5.1
is hereby amended to add the following patent cases: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>00480/1059<BR>
00480/1075<BR>
00480/1164<BR>
00480/1200<BR>
00480/1201<BR>
2475/8170<BR>
00480/1218<BR>
00650/1003<BR>
2063/8460 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;Exhibit&nbsp;5.2
is hereby amended to add the following patent cases: </FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>00050/48377<BR>
00050/49589<BR>
00050/49033<BR>
00050/49619<BR>
00050/49931 </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;In
addition, each of Exhibits 5.1 and 5.2 are hereby amended to incorporate any and all patents and/or patent applications, including but not limited to all
divisionals, continuations, continuations in part, reissues, renewals, extensions and supplementary protection certificates thereof and therefor, existing anywhere in the world, not specifically
listed but which otherwise are owned by Seller and: </FONT></P>

<UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;in
the case of Exhibit&nbsp;5.1, relate exclusively to the Pharmaceutical Field and/or the BASF Pharmaceutical Business; and </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;in
the case of Exhibit&nbsp;5.2, relate but not exclusively relate to the Pharmaceutical Field and/or the BASF Pharmaceutical Business. </FONT></P>

</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=19,SEQ=19,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=354955,FOLIO='19',FILE='DISK016:[01CHI1.01CHI1831]KC1831B.;11',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_20"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;2.24.&nbsp;&nbsp;Exhibit&nbsp;7.4 to the Purchase Agreement is hereby amended by amending and restating such exhibit in its entirety as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Knoll India Net Asset Value Statement  </B></FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp; </FONT> <FONT SIZE=2><B>Exhibit&nbsp;7.4  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> Section&nbsp;1<BR>
Knoll India Net Asset Value Calculation  </B></FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>1.1</FONT></DT><DD><FONT SIZE=2>(a)&nbsp;&nbsp;Prior
to the Closing, Seller shall ascertain the aggregate value of the net assets of Knoll India (the "Knoll India Reference
Net Asset Value") as of September&nbsp;30, 2000 on the basis of the unaudited proforma balance sheet contained in the attached Exhibit&nbsp;9.1(a), and adjusted to eliminate Cash, Financial Debt,
deferred Taxes and Accrued Taxes. </FONT></DD></DL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>(b)&nbsp;&nbsp;(i)&nbsp;&nbsp;If
the value of the net assets of Knoll India as of the Closing as determined in accordance with the principles set forth in Section&nbsp;2 below and as shown
on the Knoll India Closing Net Asset Value Statement (hereinafter referred to as the "Knoll India Closing Net Asset Value") is less than the Knoll
India Reference Net Asset Value, Seller shall pay to Purchaser Seller's pro rata share, in accordance with its percentage interest in Knoll India as of the Closing, of the amount by which the Knoll
India Closing Net Asset Value is less than the Knoll India Reference Net Asset Value. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;If
the Knoll India Closing Net Asset Value exceeds the Knoll India Reference Net Asset Value, such excess (the "Knoll India Net Assets Amount") shall be paid pro
rata to Seller in accordance with its percentage interest in Knoll India as of the Closing. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>1.2</FONT></DT><DD><FONT SIZE=2>Each
of the amounts determined in accordance with Section&nbsp;1.1(b)(i)&nbsp;above shall be paid by Seller within 5 working days after the
applicable Closing Net Asset Value Statement has become final in accordance with Section&nbsp;2.4 hereof in immediately available funds to Citibank, N.A., New York, New York (ABA #021000089) for
credit to Abbott Laboratories ***. Any credit to Purchaser shall be made in U.S. dollars at the spot exchange rate in effect at two business days prior to the date of payment. </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER"><FONT SIZE=2><B>Section&nbsp;2<BR>
Final Closing Knoll India Net Asset Value Statement  </B></FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>2.1</FONT></DT><DD><FONT SIZE=2>For
the purpose of determining the amount of the payments, if any, pursuant to Section&nbsp;1 above, Seller shall deliver to Purchaser as
promptly as practicable (but in any event no later than 15 working days) after the Closing a condensed balance sheet of Knoll India, certified by Knoll </FONT></DD></DL>
</UL>
</UL>
<HR NOSHADE ALIGN="LEFT" WIDTH="120">

<P><FONT SIZE=2>***
Confidential information omitted pursuant to a request for confidential treatment filed separately with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=20,SEQ=20,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=812632,FOLIO='20',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_21"> </A>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>India's
chief financial officer (hereinafter referred to as "Knoll India Closing Net Asset Value Statement") reflecting the Knoll India Closing Net Asset Value. The Knoll India Closing Net Asset Value
Statement shall be prepared in accordance with the Report Principles (as defined in Section&nbsp;13.20(a) of the Agreement) as of the Closing Date, shall be prepared and consolidated in a manner
consistent with Exhibit&nbsp;9.1(a), shall fairly present the net assets of Knoll India as of the Closing Date, and shall be adjusted in a manner consistent with Exhibit&nbsp;9.1(b) (to the extent
applicable) and further adjusted in accordance with the principles set forth in Exhibit&nbsp;10.1 hereto (to the extent applicable). </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>2.2</FONT></DT><DD><FONT SIZE=2>Purchaser
shall have 10 working days after receipt of the Knoll India Closing Net Asset Value Statement during which it may review such Closing Net
Asset Value Statement, and raise in writing and in reasonable detail any objections against specified items such Closing Net Asset Value Statement, indicating precisely the higher or lower value which
in Purchaser's opinion should be allocated to each item in dispute. During this period of time, Purchaser and its auditors shall be granted access to all relevant information produced by Seller or
Seller's Auditors. Any item in the Knoll India Closing Net Asset Value Statement objected to by Purchaser shall hereinafter be referred to as an "Knoll India Disputed Item".
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.3</FONT></DT><DD><FONT SIZE=2>If
and insofar as Purchaser does not raise objections to the Knoll India Closing Net Asset Value Statement in accordance with Section&nbsp;2.2
above, the Closing Net Asset Value arrived at in the Knoll India Closing Net Asset Value Statement shall be final and binding upon the parties. To the extent that the Net Asset Value arrived at in the
Knoll India Closing Net Asset Value Statement is final and binding upon the parties, the adjustment payment to be made by Purchaser or Seller according to Section&nbsp;1 above shall be made in
accordance with such Section.
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.4</FONT></DT><DD><FONT SIZE=2>The
parties shall use their best efforts to resolve the Knoll India Disputed Items within 15 working days following the receipt by Seller of
Purchaser's objections pursuant to Section&nbsp;2.3 above.
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.5</FONT></DT><DD><FONT SIZE=2>Any
Knoll India Disputed Items not resolved pursuant to Section&nbsp;2.4 above shall be submitted by the parties to Ernst&nbsp;&amp; Young for
review. Should Ernst&nbsp;&amp; Young become unavailable, the parties shall mutually agree on another accounting firm of international standing.
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.6</FONT></DT><DD><FONT SIZE=2>In
rendering its decision, the accounting firm shall consider only the Knoll India Disputed Items and, with respect to each such Knoll India
Disputed Item, shall stay within the range of the values allocated to it by the parties. The accounting firm shall deliver in writing to Seller and Purchaser as promptly as practicable its
determination of the Knoll India Disputed Items stating the reasons of its decision. The reasons shall specifically </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=21,SEQ=21,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=502682,FOLIO='21',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_22"> </A>
<UL>
<UL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>address
the arguments brought forward by the parties with respect to each Knoll India Disputed Item. Such determination shall be final and binding upon the parties absent manifest mathematical errors.
The accounting firm shall allocate its fees to the parties in accordance with &sect;&sect; 91 et seq. of the German Civil Procedure. </FONT></P>

</UL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.25.&nbsp;&nbsp;A
new Exhibit&nbsp;11.1.1(d) to the Purchase Agreement is hereby created and is as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Exhibit&nbsp;11.1.1(d)  </B></FONT></P>

<UL>
<UL>

<P><FONT SIZE=2>The
Hokuriku Shares owned by Lupharma and Transpharm shall be duly and validly transferred by Lupharma and Transpharm directly to the Seller, and the Seller shall duly and validly transfer such shares
directly to KPC pursuant to the Share Sale and Transfer Agreement ("KPC Hokuriku Shares Agreement"). For the avoidance of doubt, such shares, as transferred to KPC, shall, for purposes of the Purchase
Agreement, be deemed "Shares." </FONT></P>

<P><FONT SIZE=2>At
Closing, the Promissory Note issued by KPC pursuant to the KPC Hokuriku Shares Agreement is hereby assigned to Purchaser by its holder upon payment of the Aggregate Purchase Price. </FONT></P>

<P><FONT SIZE=2>Any
stamp or transfer taxes or VAT incurred in connection with the transfers contemplated by this Exhibit&nbsp;11.1.1(d) shall be borne by Purchaser. </FONT></P>


<P><FONT SIZE=2>Purchaser
shall not make any Section&nbsp;338(h)(10) election with respect to the acquisition by it of the Hokuriku Shares. </FONT></P>

</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.26.&nbsp;&nbsp;A
new Exhibit&nbsp;11.1.1(e) to the Purchase Agreement is hereby created and is as follows: </FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B>Exhibit&nbsp;11.1.1(e)  </B></FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>(a)
Seller shall cause the Shares of Knoll Pharmaceuticals&nbsp;Ltd. (India) ("Knoll India") owned by Lupharma to be duly and validly transferred
by Lupharma to a newly-formed corporation organized under the laws of the United Kingdom and wholly owned by the Seller or any Affiliate of Seller other than the Companies ("BASF UK Public Holding
Company"). </FONT></DD></DL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>(b)
Seller shall then cause, on the Closing Date, all of the issued and outstanding shares of BASF UK Public Holding Company to be duly and validly transferred to the Purchaser entity, Abbott Equities
Holdings Limited, a U.K. company. </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Seller
shall cause the Shares of Knoll International&nbsp;Ltd. (India) ("Knoll Private") owned by Knoll AG to be duly and validly transferred by
Knoll </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="RIGHT"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=22,SEQ=22,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=194676,FOLIO='22',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_23"> </A>
<UL>
<UL>
</UL>
</UL>
<UL>
<UL>
<UL>

<P><FONT SIZE=2>AG
to a newly-formed corporation (other than BASF UK Public Holding Company) that is organized under the laws of the United Kingdom and wholly owned by the Seller or any Affiliate of Seller other than
the Companies ("BASF UK Private Holding Company"). </FONT></P>

</UL>
<DL compact>
<DT><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Any
stamp or transfer taxes or VAT incurred in connection with the transfers contemplated by paragraphs 1(a) and 2 of this Exhibit&nbsp;11.1.1(e)
(the "India Transfers") shall be borne by Purchaser.
<BR><BR></FONT></DD><DT><FONT SIZE=2>4.</FONT></DT><DD><FONT SIZE=2>For
the avoidance of doubt, in addition to Knoll India, the BASF UK Public Holding Company shall, for purposes of the Purchase Agreement, be deemed
an "Other Foreign Subsidiary." </FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.27.&nbsp;&nbsp;A
new Exhibit&nbsp;12.2(d) to the Purchase Agreement is hereby created and is as follows: </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2><B>Exhibit&nbsp;12.2(d)  </B></FONT></P>

<P ALIGN="CENTER"><FONT SIZE=2><B> Excluded Companies  </B></FONT></P>

<UL>
<UL>
<DL compact>
<DT><FONT SIZE=2>1.</FONT></DT><DD><FONT SIZE=2>Boots
Galenika d.o.o. (Yugoslavia)
<BR><BR></FONT></DD><DT><FONT SIZE=2>2.</FONT></DT><DD><FONT SIZE=2>Knoll
Polska Sp zoo (Poland)
<BR><BR></FONT></DD><DT><FONT SIZE=2>3.</FONT></DT><DD><FONT SIZE=2>Knoll
Pharmaceutical PTE&nbsp;Ltd. (Singapore)
<BR><BR></FONT></DD><DT><FONT SIZE=2>4.</FONT></DT><DD><FONT SIZE=2>Knoll
AG&nbsp;&amp; Co OHG
<BR><BR></FONT></DD><DT><FONT SIZE=2>5.</FONT></DT><DD><FONT SIZE=2>Minden
Farmaceutical Lda.
<BR><BR></FONT></DD><DT><FONT SIZE=2>6.</FONT></DT><DD><FONT SIZE=2>Knoll
International Private&nbsp;Ltd. (India) and BASF UK Private Holding Company
<BR><BR></FONT></DD><DT><FONT SIZE=2>7.</FONT></DT><DD><FONT SIZE=2>Latinoamericana
de Farmacos Lda. (Colombia)
<BR><BR></FONT></DD><DT><FONT SIZE=2>8.</FONT></DT><DD><FONT SIZE=2>BASF
Management Services S.A. (Spain)
<BR><BR></FONT></DD><DT><FONT SIZE=2>9.</FONT></DT><DD><FONT SIZE=2>Knoll
Centroamericana (Guatemala)
<BR><BR></FONT></DD><DT><FONT SIZE=2>10.</FONT></DT><DD><FONT SIZE=2>Transpharm,&nbsp;Inc.
</FONT></DD></DL>
</UL>
</UL>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.28.&nbsp;&nbsp;Exhibit&nbsp;8.1
is amended and restated in its entirety as attached hereto as Exhibit&nbsp;8.1. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.29.&nbsp;&nbsp;Exhibit&nbsp;13.21
to the Purchase Agreement is hereby amended by deleting therefrom "Development and Distribution Agreement between Knoll,&nbsp;Ltd. and Byk
Gulden, dated May&nbsp;1, 1996." </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.30.&nbsp;&nbsp;A
new Exhibit&nbsp;13.29 to the Purchase Agreement is hereby created and is attached hereto as Exhibit&nbsp;13.29. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.31.&nbsp;&nbsp;A
new Exhibit&nbsp;15.1(I)(d) to the Purchase Agreement is hereby created and is attached hereto as Exhibit&nbsp;15.1(I)(d). </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;2.32.&nbsp;&nbsp;The
Purchase Agreement is hereby amended by replacing, in every provision in which it occurs, the existing term "Separate Sale and Transfer Contracts" with the
term "Separate Transfer Contracts." </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=23,SEQ=23,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=895893,FOLIO='23',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_24"> </A>
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kc1831_section_3_miscellaneous"> </A>
<A NAME="toc_kc1831_4"> </A>
<BR></FONT><FONT SIZE=2><B>Section&nbsp;3<BR>  Miscellaneous    <BR>  </B></FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.1.&nbsp;&nbsp;Notices.
All notices, statements and other communications to be given with respect to this Amendment shall be in the English language and sent by registered mail,
by facsimile transmission or by messenger to the parties at the following addresses or at such other addresses as shall be specified by the parties: </FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="TOP">
<TD WIDTH="20%"><FONT SIZE=2>If to Seller:</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2>BASF Aktiengesellschaft<BR>
Central Legal Department<BR>
67056 Ludwigshafen, Germany<BR>
Telefax: 49.621.60.20410</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="20%"><FONT SIZE=2><BR>
If to Purchaser:</FONT></TD>
<TD WIDTH="4%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="76%"><FONT SIZE=2><BR>
Abbott Laboratories<BR>
One Abbott Park Road<BR>
Abbott Park, Illinois 60053-3500<BR>
Telephone: 847-937-6100<BR>
Attn: General Counsel</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.2.&nbsp;&nbsp;Entire
Agreement; Written Form. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
The Purchase Agreement as amended by this Amendment constitutes the entire agreement and supersedes all other prior agreements and undertakings both written and
oral among the parties with respect to the subject matter thereof and hereof. In the event of any translation of this Amendment, the English version shall govern. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
Any changes in this Amendment including, but not limited to, this clause shall only be valid if made in writing and executed by both Seller and Purchaser or, if
necessary, in a stricter form. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.3.&nbsp;&nbsp;Assignment;
Set-off. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
Neither Seller nor Purchaser may assign any rights or obligations under this Amendment to any third party without the consent of the respective other party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
Purchaser shall not be entitled to offset any claim it may have against Seller (whether under this Amendment or otherwise) against the claim of Seller for payment
of the Aggregate Purchase Price
pursuant to Section&nbsp;8 of the Purchase Agreement as amended by this Amendment unless Purchaser's claim has become final (rechtskr&auml;ftig) or is undisputed. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.4.&nbsp;&nbsp;Governing
Law, Jurisdiction. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
This Amendment shall be governed by and construed in accordance with the laws of the Federal Republic of Germany, without regard to its choice of law rules. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=24,SEQ=24,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=1000834,FOLIO='24',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<A NAME="page_kc1831_1_25"> </A>

<P><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as otherwise expressly stated elsewhere in this Amendment, all disputes arising out of or in connection with this Amendment, including any question
regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration in accordance with the Rules of the German Institute of Arbitration e.V. (DIS) without
recourse to the ordinary courts of law, provided that the Chairman of the Arbitral Tribunal shall not be of the same nationality as that of any of the parties to a given dispute. The place of
arbitration shall be Frankfurt; the language of the arbitration shall be English. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.5.&nbsp;&nbsp;Expenses. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)
Except as specifically provided otherwise in this Amendment, each party shall bear its own expenses and fees (including attorneys', accountants', consultants' and
advisors' fees) in connection with this Amendment or any of the transactions contemplated herein, including any merger control filing and filings with other governmental authorities made by such
party. </FONT></P>

<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)
Fees and costs triggered by the implementation of this Amendment, including but not limited to any notarial fees, any transfer or sales Tax (including value added
Tax and stamp duties and property transfer Tax according to &sect; 5 para 3 Grunderwerbssteuergesetz), any registration or publication fees shall be borne by Purchaser. </FONT></P>


<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;3.6.&nbsp;&nbsp;Severability.
Should any of the provisions of this Amendment be or become fully or partly invalid or unenforceable, the remainder of the Amendment shall be valid
or enforceable. The invalid or unenforceable provision shall be replaced by a provision which shall come as close as possible to the economic purpose of the invalid provision. Any gaps in this
Amendment shall be filled by a provision which the parties as prudent businessmen would in good faith have agreed to, had they considered the matter not covered by this Amendment. </FONT></P>

<P ALIGN="RIGHT"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<!-- ZEQ.=25,SEQ=25,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=799934,FOLIO='25',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<P ALIGN="CENTER"><FONT SIZE=2><A
NAME="kc1831_list_of_exhibits_to_the__kc102296"> </A>
<A NAME="toc_kc1831_5"> </A>
<BR></FONT><FONT SIZE=2>LIST OF EXHIBITS TO THE AMENDMENT TO PURCHASE AGREEMENT    <BR></FONT></P>

<!-- User-specified TAGGED TABLE -->
<TABLE WIDTH="100%" BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR VALIGN="BOTTOM">
<TH WIDTH="30%" ALIGN="LEFT"><FONT SIZE=2>EXHIBIT NUMBER<BR></FONT>
<BR></TH>
<TH WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH WIDTH="64%" ALIGN="LEFT"><FONT SIZE=2>EXHIBIT DESCRIPTION<BR></FONT>
<BR></TH>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2>Exhibit&nbsp;8.1</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2>Allocation of Aggregate Purchase Price</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2>Exhibit&nbsp;12.5</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2>List of deferred closings</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2>Exhibit&nbsp;13.29</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2>Description of Chain of Title of Hokuriku</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2>Exhibit&nbsp;15.1(I)(d)</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2>Description of Damages pursuant to Section&nbsp;15.1(I)(d)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD WIDTH="30%"><FONT SIZE=2>Exhibit 19.3</FONT></TD>
<TD WIDTH="6%"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD WIDTH="64%"><FONT SIZE=2>Form of Omnibus Intercompany Obligation Agreement</FONT></TD>
</TR>
</TABLE>
<!-- end of user-specified TAGGED TABLE -->
<P><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;These exhibits are omitted as permitted under Item&nbsp;601(b)(2) of Regulation&nbsp;S-K. Abbott agrees to furnish supplementally a copy of any omitted
exhibit to the Amendment to Purchase Agreement to the Commission upon request. </FONT></P>

<HR NOSHADE>
<!-- ZEQ.=26,SEQ=26,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2",CHK=498113,FOLIO='blank',FILE='DISK016:[01CHI1.01CHI1831]KC1831C.;5',USER='CHANSON',CD='15-MAR-2001;20:23' -->
<!-- Generated by Merrill Corporation (www.merrillcorp.com) -->
<BR>
<P><br><A NAME="01CHI1831_2">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2><A HREF="#toc_kc1831_1">Amendment to Purchase Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kc1831_2">Section 1 Definitions</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kc1831_3">Section 2 Amendments to Purchase Agreement</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kc1831_4">Section 3 Miscellaneous</A></FONT><BR>
<FONT SIZE=2><A HREF="#toc_kc1831_5">LIST OF EXHIBITS TO THE AMENDMENT TO PURCHASE AGREEMENT</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=JKANTOR,SEQ=,EFW="2040697",CP="ABBOTT LABORATORIES",DN="2" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
